ArticleCardio-oncology (London, England)2025
Cardiomyocyte overexpression of microRNA-210 mitigates apoptotic cell death induced by doxorubicin.
Article in Cardio-oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdvancements in cancer diagnostics and treatments have significantly increased patient survival rates. However, these advancements are often accompanied by treatment-induced health issues. Among these, chemotherapy-induced cardiac damage is particularly concerning, with doxorubicin being notably cardiotoxic. Despite extensive research, effective strategies to protect the heart from doxorubicin-induced cardiotoxicity remain elusive. This study aims to investigate whether miR-210, which has previously shown cardioprotective properties against ischemic heart disease, can offer protection against doxorubicin-induced cardiotoxicity.
methodsmiR-210 was upregulated or downregulated in AC-16 cardiomyocytes using transient expression or decoy/inhibitory transfection vectors before being subjected to 5 µM doxorubicin treatment for 24 h. Cell death was determined using a lactate dehydrogenase release assay. Apoptotic cell death was determined by a caspase-3 activity assay, and the Akt-GSK-3β signaling pathway was explored using a sandwich enzyme-linked immunosorbent assay (ELISA) approach.
resultsOverexpression of miR-210 in AC-16 cardiomyocytes exposed to 24 h of doxorubicin treatment caused a significant reduction in cell death and a significant reduction in apoptotic cell death, measured by caspase-3 activity. Downregulation of miR-210 in AC-16 cardiomyocytes exposed to the same conditions resulted in a significant increase in apoptotic cell death. An increase in phosphorylation of GSK-3β at the inhibitory p-Ser9 site and the Akt activating site p-Ser473 was observed in the miR-210 overexpression group, while a decrease in p-Ser473 Akt but no difference in p-Ser9 GSK-3β was observed in the miR-210-downregulated group.
conclusionmiR-210 exerts cardioprotective effects in AC-16 cardiomyocytes exposed to 24 h of doxorubicin treatment by reducing cell death and inhibiting caspase-3 dependent apoptosis through modulation of the Akt-GSK-3β signaling pathway. This study suggests a novel role for miR-210 in mitigating DOX-induced cardiomyocyte death, potentially laying the foundation for new treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.